Characterization of the tumor immune microenvironment (TME) in early stage HR-positive HER2-positive breast cancer

被引：0
|
作者：
Fenn, Kathleen M. [1 ]
Marks, Douglas K. [2 ]
Vanguri, Rami [1 ]
Boboila, Shuobo [1 ]
Guo, Hua [1 ]
Hibshoosh, Hanina [1 ]
Kalinsky, Kevin [1 ]
Connolly, Eileen [1 ]
机构：
[1] Columbia Univ, Irving Med Ctr, New York, NY USA
[2] NYU, New York, NY USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 04期
关键词：
D O I：
10.1158/1538-7445.SABCS19-P6-10-25
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P6-10-25
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Optimizing treatment for HER2-positive HR-positive breast cancer
    Debien, Veronique
    de Azambuja, Evandro
    Piccart-Gebhart, Martine
    CANCER TREATMENT REVIEWS, 2023, 115
  • [2] Retrospective single case reports on the treatment of patients with HER2-positive/HR-positive early breast cancer with neratinib (IRENE)
    Tribian, N.
    Goehler, T.
    Baesecke, J.
    Guth, D.
    Vannier, C.
    Petru, E.
    Maass, N.
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 : 171 - 171
  • [3] Characterization of the immune tumor microenvironment of HER2-positive breast cancer following treatment with entinostat and immune checkpoint inhibition.
    Torres, Evanthia T. Roussos
    Sidiropoulos, Dimitrios N.
    Davis-Marcisak, Emily
    Kagohara, Luciane Tsukamoto
    Connolly, Roisin M.
    Stearns, Vered
    Jaffee, Elizabeth M.
    Fertig, Elana J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [4] Ribociclib in HR-positive, HER2-negative breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2016, 17 (11): : E482 - E482
  • [5] Neratinib for the treatment of HER2-positive early stage breast cancer
    Echavarria, Isabel
    Lopez-Tarruella, Sara
    Marquez-Rodas, Ivan
    Jerez, Yolanda
    Martin, Miguel
    EXPERT REVIEW OF ANTICANCER THERAPY, 2017, 17 (08) : 669 - 679
  • [6] Optimal treatment of early stage HER2-positive breast cancer
    Pernas, Sonia
    Barroso-Sousa, Romualdo
    Tolaney, Sara M.
    CANCER, 2018, 124 (23) : 4455 - 4466
  • [7] Personalized treatment for early stage HER2-positive breast cancer
    Prat, A.
    CANCER RESEARCH, 2021, 81 (04)
  • [8] Neratinib in Early-Stage HER2-Positive Breast Cancer
    Cherian, Mathew A.
    Ma, Cynthia X.
    BREAST DISEASES, 2015, 26 (04): : 285 - 287
  • [9] How we treat HR-positive, HER2-negative early breast cancer
    Lopez-Tarruella, Sara
    Echavarria, Isabel
    Jerez, Yolanda
    Herrero, Blanca
    Gamez, Salvador
    Martin, Miguel
    FUTURE ONCOLOGY, 2022, 18 (08) : 1003 - 1022
  • [10] Updates to the Management of HR-Positive, HER2-Negative Breast Cancer
    Gradishar, William J.
    JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2024, 22
12345